Payment overview · 2025
General Payments
$991.87
40 reported records · 15 companies
Healthcare provider profile · identity verified
Hans Yu, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN FRANCISCO, CA · NPI 1811089303
Verified facts
What the public records show
CMS Open Payments records show Hans Yu, D.O. received $991.87 in general payments during 2025 across 40 reported records.
PFIZER INC. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Eliquis, Jardiance, Ozempic, Paxlovid, Prolia, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $226.72 | 22.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $159.08 | 16.0% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $106.47 | 10.7% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $81.02 | 8.2% | 3 | 2025 |
| Evofem Biosciences, Inc. | Unresolved — no canonical attribution shown | $63.31 | 6.4% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $62.92 | 6.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.17 | 4.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.58 | 4.8% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.74 | 3.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.42 | 3.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.42 | 3.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.28 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.91 | 2.5% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.69 | 2.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.14 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $991.87 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $147.67 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $135.53 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $135.53 | 6 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $81.02 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $81.02 | 3 | 2025 |
Source payment records
|
|||||
| Phexx Normalized: phexx |
Drug | Evofem Biosciences, Inc. | $63.31 | 7 | 2025 |
Source payment records
|
|||||
| Phexxi Normalized: phexxi |
Drug | Evofem Biosciences, Inc. | $63.31 | 7 | 2025 |
Source payment records
|
|||||
| Solosec Normalized: solosec |
Drug | Evofem Biosciences, Inc. | $63.31 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $62.92 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.41 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $56.81 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $56.81 | 2 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $49.44 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $48.17 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $48.17 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.94 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $35.74 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.42 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.42 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.42 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $30.96 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $28.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 211 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 48 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 126 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 213 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 72 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 48 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 172 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
48 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
213 | 49 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
108 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
48 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
172 | 124 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
213 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
211 | 211 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
72 | 72 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1734 | 490 |
| Amlodipine Besylate | Amlodipine Besylate | 982 | 266 |
| Metformin Hcl | Metformin Hcl | 704 | 187 |
| Metoprolol Succinate | Metoprolol Succinate | 573 | 157 |
| Losartan Potassium | Losartan Potassium | 506 | 134 |
| Simvastatin | Simvastatin | 490 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 85 |
| Lisinopril | Lisinopril | 248 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 226 | 65 |
| Pioglitazone Hcl | Pioglitazone Hcl | 224 | 58 |
| Alendronate Sodium | Alendronate Sodium | 218 | 73 |
| Jardiance | Empagliflozin | 213 | 49 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 211 | 211 |
| Omeprazole | Omeprazole | 186 | 70 |
| Januvia | Sitagliptin Phosphate | 183 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 55 |
| Valsartan | Valsartan | 178 | 55 |
| Gabapentin | Gabapentin | 173 | 61 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 172 | 124 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 155 | 153 |
| Irbesartan | Irbesartan | 134 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 130 | 38 |
| Meloxicam | Meloxicam | 128 | 60 |
| Eliquis | Apixaban | 126 | 31 |
| Allopurinol | Allopurinol | 125 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 121 | 64 |
| Donepezil Hcl | Donepezil Hcl | 116 | 29 |
| Atenolol | Atenolol | 109 | 30 |
| Finasteride | Finasteride | 109 | 32 |
| Vemlidy | Tenofovir Alafenamide | 108 | 15 |
| Furosemide | Furosemide | 104 | 30 |
| Glipizide | Glipizide | 100 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 94 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 23 |
| Famotidine | Famotidine | 83 | 28 |
| Ezetimibe | Ezetimibe | 78 | 27 |
| Fenofibrate | Fenofibrate | 78 | 23 |
| Trazodone Hcl | Trazodone Hcl | 75 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 72 | 72 |
| Lovastatin | Lovastatin | 71 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 24 |
| Xarelto | Rivaroxaban | 68 | 13 |
| Carvedilol | Carvedilol | 65 | 15 |
| Nabumetone | Nabumetone | 64 | 38 |
| Fenofibrate | Fenofibrate,micronized | 63 | 17 |
| Glimepiride | Glimepiride | 62 | 20 |
| Raloxifene Hcl | Raloxifene Hcl | 60 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 24 |
| Mometasone Furoate | Mometasone Furoate | 59 | 45 |
| Naproxen | Naproxen | 59 | 32 |
| Entecavir | Entecavir | 58 | 11 |
| Mirtazapine | Mirtazapine | 56 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 54 | 15 |
| Celecoxib | Celecoxib | 51 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 33 |
| Benazepril Hcl | Benazepril Hcl | 49 | 13 |
| Hydrocortisone | Hydrocortisone | 49 | 26 |
| Metformin Hcl Er | Metformin Hcl | 49 | 17 |
| Nifedipine Er | Nifedipine | 49 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 48 | 48 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 48 | 27 |
| Prolia | Denosumab | 48 | 27 |
| Cephalexin | Cephalexin | 47 | 43 |
| Lorazepam | Lorazepam | 46 | 15 |
| Azithromycin | Azithromycin | 45 | 41 |
| Montelukast Sodium | Montelukast Sodium | 45 | 14 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 11 |
| Potassium Chloride | Potassium Chloride | 43 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Prednisone | Prednisone | 41 | 16 |
| Meclizine Hcl | Meclizine Hcl | 40 | 31 |
| Ozempic | Semaglutide | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | 12 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Vascepa | Icosapent Ethyl | 36 | suppressed |
| Colchicine | Colchicine | 32 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Felodipine Er | Felodipine | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 16 |
| Amoxicillin | Amoxicillin | 26 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Dutasteride | Dutasteride | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 12 |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lamivudine Hbv | Lamivudine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $991.87 · 40 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, EVENITY, GARDASIL 9, JARDIANCE, KISUNLA, KRYSTEXXA, LEQVIO, M-M-R II, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, PYRUKYND, Phexx, Phexxi, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Solosec, UBRELVY, ZAVZPRET | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error